Latest news newssearch boxGO 26 Jul 2019 Janssen reports positive top-line Phase 3 results for ponesimod in adults with relapsing multiple sclerosis 23 Jul 2019 Idorsia announces financial results for the first half of 2019 13 Jun 2019 Efficacy and safety data with Idorsia's dual orexin receptor antagonist presented at SLEEP 2019 in San Antonio 03 May 2019 Idorsia holds its second Annual General Meeting of Shareholders - All Board proposals approved 18 Apr 2019 Idorsia announces financial results for the first quarter 2019 29 Mar 2019 Idorsia issues invitation to 2019 Annual General Meeting of Shareholders 07 Feb 2019 Idorsia announces financial results for 2018 - outstanding progress made - four late stage assets advanced into Phase 3 05 Feb 2019 Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with clazosentan 07 Jan 2019 Idorsia initiates a multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus 18 Dec 2018 Idorsia's P2Y12 receptor antagonist - selatogrel - Phase 2 clinical studies meet their objective 20 Nov 2018 Santhera enters into agreement to acquire option from Idorsia for exclusive sub-license of first-in-class dissociative steroid vamorolone 05 Nov 2018 Idorsia maintains collaboration agreement with ReveraGen 24 Oct 2018 Company statement 23 Oct 2018 Idorsia financial results for the first nine months of 2018 23 Oct 2018 Idorsia announces that Simon Jose is to join the company as Chief Commercial Officer 24 Jul 2018 Idorsia announces financial results for the first half 2018 11 Jul 2018 Idorsia successfully completes the offering of new shares and the offering of convertible bonds thereby securing long-term funding for the development of its advancing pipeline 10 Jul 2018 Idorsia launches the offering of new shares in combination with the offering of convertible bonds to fund the development of its advancing pipeline 20 Jun 2018 Idorsia initiates PRECISION - Phase 3 study with aprocitentan for resistant hypertension management 18 Jun 2018 Idorsia is initiating REACT - Phase 3 registration study with clazosentan 1 2 3
